GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » 3-Year EPS without NRI Growth Rate

Theriva Biologics (FRA:SFY) 3-Year EPS without NRI Growth Rate : 44.30% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Theriva Biologics 3-Year EPS without NRI Growth Rate?

Theriva Biologics's EPS without NRI for the three months ended in Mar. 2024 was €-0.28.

During the past 3 years, the average EPS without NRI Growth Rate was 44.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 52.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 43.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Theriva Biologics was 65.70% per year. The lowest was -68.10% per year. And the median was 39.70% per year.


Competitive Comparison of Theriva Biologics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Theriva Biologics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's 3-Year EPS without NRI Growth Rate falls into.



Theriva Biologics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Theriva Biologics  (FRA:SFY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Theriva Biologics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (FRA:SFY) Business Description

Industry
Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-25-2022